A series of 3-[(4-arylpiperaz-1-yl) alkylamino]-2H-1, 4-benzoxazines were prepared and their affinities for cloned human D2, D3, and D4 dopamine receptor subtypes were measured. This led to the identification of 1a, 1f, and 1g as high affinity selective antagonists at the D4 receptor.
